Tarsus Pharmaceuticals, Inc.

TARS - CIK 0001819790

Market cap$2.66 B

Rank#1900

SEC filings617

Tarsus Pharmaceuticals, Inc. trades as TARS and has a market capitalization of $2.66 B, making it the #1900 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $451.36M, up 146.7% from the prior year and net income of -$66.00M. This page tracks Tarsus Pharmaceuticals, Inc. through 617 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$451.36MFY 2025

Net income (latest FY)-$66.00MFY 2025

Operating cash flow (latest FY)-$12.45MFY 2025

Total assets (latest FY)$562.16MFY 2025

Net margin-14.6%latest FY

Financial performance

Net profit margin expanded from -24.2% to -14.6% over the same period - every figure below comes from the company's audited annual filings.

TARS annual revenueView details

TARS annual net incomeView details

Key statistics

Market cap: $2.66 B
Share price (derived)market cap / shares outstanding: $61.91
EPS (diluted)FY 2025: $-1.59
Shares outstandingas of 2026-05-01: 0.04B
Total equityas of 2026-03-31: $348.95M
Return on equity: -18.9%
Long-term debtas of 2026-03-31: $72.60M
Cash & equivalentsas of 2026-03-31: $102.19M

Latest filings

Filing	Type	Filed
SCHEDULE 13G	-	2026-05-15
SCHEDULE 13G/A	-	2026-05-15
SCHEDULE 13G/A	-	2026-05-08
Quarterly report	10-Q	2026-05-06
Major company event	8-K	2026-05-06
SCHEDULE 13G/A	-	2026-05-06
Annual report to shareholders	ARS	2026-04-28
Proxy materials	DEFA14A	2026-04-28

Browse the full filing history (617 filings)

Recent press releases

Tarsus to Participate in Upcoming Investor Conferences2026-05-28
Tarsus to Participate in Upcoming Investor Conferences | Tarsus Pharmaceuticals
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans2026-05-14
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans | Tarsus Pharmaceuticals
Tarsus to Participate in Upcoming Investor Conferences2026-05-07
Tarsus to Participate in Upcoming Investor Conferences | Tarsus Pharmaceuticals
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements2026-05-06
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements | Tarsus Pharmaceuticals
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 20262026-05-06
Our Story Serving patient needs is our passion; delivering revolutionary treatments is our mission

Similar companies

The largest companies sharing Tarsus Pharmaceuticals, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).

AMGNAmgen Inc.$183.41 B TARS vs AMGN

GILDGilead Sciences, Inc.$151.05 B TARS vs GILD

ARGXargenx SE$53.35 B TARS vs ARGX

RVMDRevolution Medicines, Inc.$30.65 B TARS vs RVMD

BIIBBiogen Inc.$28.68 B TARS vs BIIB

Frequently asked questions

What is Tarsus Pharmaceuticals, Inc.'s market cap?

Tarsus Pharmaceuticals, Inc. (TARS) has a market capitalization of $2.66 B as of 2026-06-10, ranking #1900 among US-listed companies.

How much revenue does Tarsus Pharmaceuticals, Inc. make?

Tarsus Pharmaceuticals, Inc. reported revenue of $451.36M for fiscal year 2025, an increase of 146.7% year over year.

Is Tarsus Pharmaceuticals, Inc. profitable?

In its latest fiscal year Tarsus Pharmaceuticals, Inc. reported a net loss of $66.00M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.